Donate

Publication

A Framework to Advance Biomarker Development in the Diagnosis, Outcome Prediction, and Treatment of Traumatic Brain Injury

Citation:
Journal of Neurotrauma 2022; 39:436–457 doi: 10.1089/neu.2021.0099
Authored By:
Elisabeth A Wilde, Ina-Beate Wanner, Kimbra Kenney, Jessica Gill, James R Stone, Seth Disner, Caroline Schnakers, Retsina Meyer, Eric M. Prager, Magali Haas, and Andreas Jeromin
Abstract:
Multi-modal biomarkers (e.g., imaging, blood-based, physiological) of unique traumatic brain injury (TBI) endophenotypes are necessary to guide the development of personalized and targeted therapies for TBI. Optimal biomarkers will be specific, sensitive, rapidly and easily accessed, minimally invasive, cost effective, and bidirectionally translatable for clinical and research use. For both uses, understanding how TBI biomarkers change over time is critical to reliably identify appropriate time windows for an intervention as the injury evolves. Biomarkers that enable researchers and clinicians to identify cellular injury and monitor clinical improvement, inflection, arrest, or deterioration in a patient’s clinical trajectory are needed for precision healthcare. Prognostic biomarkers that reliably predict outcomes and recovery windows to assess neurodegenerative change and guide decisions for return to play or duty are also important. TBI biomarkers that fill these needs will transform clinical practice and could reduce the patient’s risk for long-term symptoms and lasting deficits. This article summarizes biomarkers currently under investigation and outlines necessary steps to achieve short- and long-term goals, including how biomarkers can advance TBI treatment and improve care for patients with TBI.
Published in:
Journal of Neurotrauma
View article

More Publications

May 19, 2023

Nature Reviews Neurology

Global synergistic actions to improve brain health for human development

View
April 20, 2023

Nature Mental Health

Machine learning-based identification of a psychotherapy-predictive electroencephalographic signature in PTSD

View
February 13, 2023

Frontiers in Aging Neuroscience

Machine learning within the Parkinson’s progression markers initiative: Review of the current state of affairs

View
September 9, 2022

Sensors

Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors

View
June 1, 2022

JAMA Network Open

Association of Posttraumatic Stress Disorder With Accelerated Cognitive Decline in Middle-aged Women

View
February 26, 2022

Translational Psychiatry

Plasma biomarkers associated with deployment trauma and its consequences in post-9/11 era veterans: initial findings from the TRACTS longitudinal cohort

View
View All

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

©2023 Cohen Veterans Bioscience |  Privacy Policy | Terms of Use

Newsletter
Donate